Markets

Empire Metals will engage with investors at the Ignite Investment Summit in Hong Kong and LME Week in London during October 2025. Management will provide updates on the Pitfield Project following the maiden Mineral Resource Estimate. Discussions will focus on the MRE’s implications, project economics, and the path to commercial production of its substantial titanium resources (2.2 billion tonnes grading 5.1% TiO₂). An updated corporate presentation is available on the company website.

Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) is expanding its *ai^² Futures Lab* program through a collaboration with the University of Oregon’s Lundquist College of Business, starting Winter 2026. This initiative connects student teams with biopharmaceutical business development projects, aiming to discover therapeutic assets and nurture future industry leaders. Students will assess early-stage pharmaceutical assets, analyze markets and intellectual property, and identify pathways for patient care. The program, part of Apimeds’ *ai^²* innovation platform, also partners with the University of Alabama and the University of San Diego.

Eisai and BioArctic’s Leqembi Iqlik, a subcutaneous formulation of lecanemab for Alzheimer’s, has been named one of TIME’s ‘Best Inventions of 2025’. This recognition highlights its potential in targeting amyloid-beta. Leqembi, developed through collaboration and based on BioArctic’s research, is approved in multiple countries for early Alzheimer’s. The subcutaneous option offers a more convenient administration route. Analysts predict this award may boost investor confidence in BioArctic and Eisai. BioArctic retains Nordic commercialization rights and receives milestone payments and royalties.

Adlai Nortye Ltd. (NASDAQ: ANL) will present on AN4035, a novel CEACAM5-targeting antibody-drug conjugate (ADC) armed with a pan-RAS(ON) inhibitor, at the AACR-NCI-EORTC conference on October 25, 2025. The presentation will highlight the company’s efforts to develop innovative cancer therapies and address challenging targets like RAS. Further details on AN4035’s scientific rationale and data will be released after the abstract is published on October 22, 2025. AN4035 is designed to potentially broaden the therapeutic window in treating RAS-driven cancers.

Spyre Therapeutics (SYRE) announced the pricing of its public offering of 14,864,865 shares at $18.50 per share, projecting $275.0 million in gross proceeds. Underwriters have a 30-day option to purchase an additional 2,229,729 shares. The offering is expected to close around October 15, 2025, pending customary conditions. Funds will support research and development of antibody therapies for IBD and other immune-mediated conditions. Jefferies, TD Securities, Leerink Partners, and Stifel acted as joint book-running managers.

Harmonic (NASDAQ: HLIT) will release its Q3 2025 financial results on November 3, 2025, after market close. A live webcast discussing the results will follow at 2:00 p.m. PT, accessible via Harmonic’s investor relations website. A replay will be available shortly after. Harmonic, a leader in virtualized broadband and video delivery solutions, caters to media companies and service providers optimizing content delivery. The company’s performance is seen as an indicator of the video streaming and broadband infrastructure market’s health.

Group 1 Automotive, Inc. (NYSE: GPI) will release its Q3 2025 financial results on October 28, 2025, before market open. A conference call, hosted by CEO Daryl Kenningham and senior management, will be held at 9:00 a.m. ET to discuss the results and answer questions. The automotive retailer’s performance is being closely watched amid industry challenges. A live webcast and presentation will be available, with a replay accessible for 30 days. Dial-in details for the live call and a subsequent telephonic replay are provided. Group 1 operates 259 dealerships in the U.S. and U.K.

Healthcare Triangle (HCTI) unveiled a strategy to reshape its scale and capital, including acquiring Teyame.AI, a $34M revenue platform which doubles HCTI’s market cap. HCTI is marketing its QuantumNexis GenAI SaaS and exploring acquisitions like Niyama and Ezovion. A warrant inducement program lowered warrant strike prices to $2.00 and issued new warrants at $3.00. HCTI’s stock traded at $2.84 on October 13, 2025, up over 31% since September, driven by its strategic move to AI-driven patient engagement and data solutions.

Mundoro Capital granted BHP a 10-year option to acquire 100% of seven Central Timok Project exploration licenses in Serbia. BHP will fund up to US$35M in exploration and milestone payments, potentially totaling ~US$48.54M. Mundoro retains a 2% NSR royalty and will initially operate the 418 km2 project, encompassing targets like Skorusa and Tilva Rosh. The deal allows Mundoro to leverage BHP’s resources while maintaining a key royalty stake in a prospective copper region.

Roadzen (RDZN) will participate in the Maxim Growth Summit (Oct 22-23) and ThinkEquity Conference (Oct 30) in New York City. CEO Rohan Malhotra will discuss AI applications, DrivebuddyAI adoption, global scaling, margin expansion, and Roadzen’s driving intelligence network. The company aims to highlight recent accomplishments and technological progress. Investors can arrange meetings through Maxim or ThinkEquity representatives. Roadzen focuses on AI-powered auto insurance solutions.